Feasibility Study on the Use of PET-MRI / 68Ga-PSMA Imaging for HIFU-focal Treatment in the Event of Recurrent Prostate Cancer After Radiotherapy - PSMA Study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Feasibility to use the PET-MRI/68Ga-PSMA imaging for Focal-HIFU guidance
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
A significant proportion of patients with localized prostate cancer, and treated for curative intent by radiotherapy, have a local recurrence. Among these patients with local recurrence, few receive curative remedial treatment but most of them are treated with palliative hormonal therapy without any chance of long-term recovery.
The use of Focused Ultrasound (HIFU) in focal treatment (only on recurrence) is an effective and not very morbid option, especially compared to surgery. The quality of this treatment is conditioned by both an early diagnosis of recurrence, a precise localization of recurrence in the prostate and a rigorous extension assessment for the detection of occult metastases.
Innovations in medical imaging have led to the development of a new generation of "hybrid" machines that combine PET (Positron Emission Tomodensitometry) and MRI (Magnetic Resonance Imaging) technology. Associated with the use of 68Gallium-labeled PSMA (Prostate-Specific Membrane Antigen), a new tracer specific for prostate cancer, the investigators believe that this PET-MRI imaging technique can:
- To identify at an early stage the metastatic patients and to allow a more adapted therapeutic management.
- A better evaluation of the limits of local recurrence and therefore a more precise definition than with MRI alone of the tumor zone to be destroyed.
Finally, the investigators believe that the PET-MRI / 68Ga-PSMA exam, used for the selection of patients eligible for focal HIFU treatment and used for the treatment itself, should allow obtaining an optimal control of the cancer recurrence with the least possible side effects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 50 years with a life expectancy of more than 5 years. Patients between the ages of 75 and 80 will need to have a G8 score \>
- •Biological recurrence after prostate radiotherapy confirmed with de Phoenix criteria (nadir + 2 ng/mL).
- •No prior or present evidence of lymph node metastasis, soft tissue metastasis or bone metastasis, assessed by the current radiographic exam (PET-Choline) AND the PET-MRI/68Ga-PSMA before Focal-HIFU.
- •Local prostate cancer recurrence confirmed by:
- •A multiparametric MRI showing a single tumor in the prostate gland at most 3 contiguous sextants confirmed by biopsies (Index tumor). Patients with multiple suspected MRI foci may be included if only one of these foci is confirmed by biopsies.
- •Index tumor confirmed by the PET-MRI/68Ga-PSMA.
- •PSA ≤ 10ng/ml.
- •Patient having been clearly informed of the study and having accepted, with sufficient reflection time, to participate by signing the informed consent form of the study.
- •Patient affiliated with health insurance or beneficiary of an equivalent plan.
Exclusion Criteria
- •Contraindications to Focal-HIFU treatment.
- •Patient with a medical contraindication to Sonovue® injection.
- •Patient with a medical contraindication to MRI.
- •History of uncontrolled cancer and / or treated for less than 5 years (with the exception of basal cell skin cancer).
- •History of sclerosis of the bladder neck or urethral stenosis.
- •Patient at risk of bleeding according to medical advice. Patient with anticoagulants therapy must receive a treatment relay.
- •Patients with unstable neurological pathology.
- •Patient who has been treated for a therapeutic trial within 30 days of enrollment or who wishes to participate in an ongoing study that may interfere with this study.
- •Legal person protected by law.
- •Patient not able to understand the objectives of the study or refusing to comply with postoperative instructions.
Outcomes
Primary Outcomes
Feasibility to use the PET-MRI/68Ga-PSMA imaging for Focal-HIFU guidance
Time Frame: At the time of the HIFU-focal treatment
The feasibility to use the PET-MRI/68Ga-PSMA imaging for Focal-HIFU guidance will be evaluated by the possibility or not to use the target tumor contouring with the TEP-IRM au \[68Ga\]PSMA. This possibility will be determine for each patient with a systematic reviewing of TEP-IRM/\[68Ga\]PSMA and the target tumor contouring by 2 experts: a nuclear medicine specialist for TEP/\[68Ga\] PSMA and a radiologist, prostate MRI specialized.
Secondary Outcomes
- Local control of tumor recurrence 6 months after Focal-HIFU guided by PET-MRI/[68Ga]PSMA imaging.(6 months after focal HIFU therapy)
- Gleason score(3 months and 6 months after focal HIFU therapy)
- Interest of hybrid PET-MRI/[68Ga]PSMA imaging compared to standard multiparametric MRI performed at the initial assessment AND 6 month after Focal-HIFU.(6 months after focal HIFU therapy)
- Extracapsular extension of prostate cancer.(3 months and 6 months after focal HIFU therapy)
- Biological recurrence(3 months and 6 months after focal HIFU therapy)
- Proportion of positives prostate biopsies(3 months and 6 months after focal HIFU therapy)
- IIEF-5 score (Sexual function questionnaire)(3 months and 6 months after focal HIFU therapy)
- Interest of hybrid PET-MRI/[68Ga]PSMA imaging compared to PET-Choline for the metastasis detection during the initial assessment of first recurrence after radiotherapy.(Screening period.)
- Metastatic free survival(Over the 6 months after focal HIFU therapy)
- QLQC30 score (Quality of life questionnaire)(3 months and 6 months after focal HIFU therapy)
- EPIC-26 score (Urinary function questionnaire)(3 months and 6 months after focal HIFU therapy)
- Adverse event evaluation(During 6 months of follow-up after focal HIFU therapy)
- Ancillary study: Measure of anti-tumoral immunity induction(Over the 6 months)
- Circulating Tumor Cells (CTC) number(Over the 6 months)
- IPSS score (Urinary function questionnaire)(3 months and 6 months after focal HIFU therapy)
- ncRNA (non-coding RNA) PCA3 (Prostate cancer gene 3) level(Over the 6 months)